Galecto Presents Updated Clinical Data At ESMO Congress 2023 And Provides Update On Phase 1b/2a GALLANT-1 Trial
Portfolio Pulse from Happy Mohamed
Galecto, Inc. (NASDAQ:GLTO) presented encouraging clinical data from its Phase 1b/2a GALLANT-1 trial at the ESMO Congress 2023. The trial studies the combination of atezolizumab and GB1211 in treating non-small cell lung cancer. The company reported a 60% response rate in patients who received GB1211 for at least three weeks, compared to a 22-38% response rate with atezolizumab monotherapy. Galecto has decided not to initiate Part B of the GALLANT-1 trial and will instead focus on severe liver diseases. The company will continue to supply GB1211 for an upcoming Phase 2 trial.
October 23, 2023 | 12:14 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Galecto's positive clinical data from the GALLANT-1 trial could boost investor confidence. However, the decision to not initiate Part B of the trial and shift focus to severe liver diseases may cause uncertainty.
The positive clinical data from the GALLANT-1 trial could be seen as a positive development for Galecto, potentially boosting investor confidence in the company's research and development capabilities. However, the decision to not initiate Part B of the trial and instead shift focus to severe liver diseases may introduce uncertainty about the company's strategic direction and potential future revenue streams.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100